1. Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies
- Author
-
Eun Beom Lee, Bok-Hyeon Im, Ji-Young Shin, Ji-Sang Chae, Pankyeom Kim, Jung-ah Choi, Se-Na Lee, Dain Son, Manki Song, Kye Sook Yi, Eunji Yang, Soo Young Lee, Hyunjoo Lee, Hayan Park, and Dong Kyun Ryu
- Subjects
RNA viruses ,0301 basic medicine ,Viral Diseases ,Physiology ,Molecular biology ,viruses ,Molecular biology assays and analysis techniques ,medicine.disease_cause ,Biochemistry ,Neutralization ,Mice ,chemistry.chemical_compound ,Influenza A Virus, H1N1 Subtype ,Medical Conditions ,0302 clinical medicine ,Antibody Specificity ,Animal Cells ,Immune Physiology ,Red Blood Cells ,Medicine and Health Sciences ,Influenza A virus ,Enzyme-Linked Immunoassays ,Antigens, Viral ,Pathology and laboratory medicine ,Immune System Proteins ,Multidisciplinary ,biology ,Vaccination ,H1N1 ,Antibodies, Monoclonal ,Medical microbiology ,Infectious Diseases ,Viruses ,Medicine ,Pathogens ,Cellular Types ,Antibody ,Research Article ,Oseltamivir ,medicine.drug_class ,Science ,Immunology ,Research and Analysis Methods ,Monoclonal antibody ,Microbiology ,Antibodies ,03 medical and health sciences ,Antigen ,Neutralization Tests ,Influenza, Human ,medicine ,Animals ,Humans ,Influenza viruses ,CAT assay ,Immunoassays ,Blood Cells ,Hemagglutination ,Organisms ,Viral pathogens ,Biology and Life Sciences ,Proteins ,Cell Biology ,Antibodies, Neutralizing ,Virology ,Influenza ,Microbial pathogens ,Molecular biology techniques ,030104 developmental biology ,chemistry ,Polyclonal antibodies ,Immunologic Techniques ,biology.protein ,030217 neurology & neurosurgery ,Orthomyxoviruses - Abstract
There are several broadly neutralizing monoclonal antibodies that neutralize influenza viruses with different mechanisms from traditional polyclonal antibodies induced by vaccination. CT149, which is one of the broadly neutralizing antibodies, was also previously reported to neutralize group 2 and some of group 1 influenza viruses (13 out of 13 tested group 2 viruses and 5 out of 11 group 1 viruses). In this study, we developed another antibody with the aim of compensating partial coverage of CT149 against group 1 influenza viruses. CT120 was screened among different antibody candidates and mixed with CT149. Importantly, although the binding sites of CT120 and CT149 are close to each other, the two antibodies do not interfere. The mixture of CT120 and CT149, which we named as CT-P27, showed broad efficacy by neutralizing 37 viruses from 11 different subtypes, of both group 1 and 2 influenza A viruses. Moreover, CT-P27 showed in vivo therapeutic efficacy, long prophylactic potency, and synergistic effect with oseltamivir in influenza virus-challenged mouse models. Our findings provide a novel therapeutic opportunity for more efficient treatment of influenza.
- Published
- 2020
- Full Text
- View/download PDF